Leilani Olea
Family · Warwick, RINPI 1346802493
Payments from drug & device makers
Across 61 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$282
- Lilly USA, LLC$276
- AbbVie$143
- Gilead$124
- Novo Nordisk$95
- Mannkind Corporation$90
- plus $450 from 14 others
What the payments were for
- Food & beverage$1,462100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 7 | $282 |
| Lilly USA, LLC | 10 | $276 |
| AbbVie | 7 | $143 |
| Gilead | 1 | $124 |
| Novo Nordisk | 6 | $95 |
| Mannkind Corporation | 5 | $90 |
| Boehringer Ingelheim | 4 | $89 |
| GSK | 4 | $65 |
| Pfizer | 3 | $48 |
| Corcept Therapeutics | 2 | $44 |
| Novartis | 2 | $41 |
| AstraZeneca | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Amgen | 1 | $15 |
| Tandem Diabetes Care, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,462 in reported general payments places this provider in the 80th percentile of 457 family providers in Rhode Island.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $7,738 |
| JardianceEmpagliflozin | 24 | $6,723 |
| GemtesaVibegron | 14 | $3,397 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,806 |
| Pregabalin | 62 | $1,829 |
| Xtampza ErOxycodone Myristate | 11 | $1,711 |
| Potassium Chloride | 60 | $1,512 |
| Oxycodone Hcl | 60 | $1,332 |
| Lisinopril | 74 | $1,182 |
| Clozapine | 56 | $1,144 |
| Lorazepam | 46 | $1,075 |
| Sertraline Hcl | 59 | $1,054 |
| Bumetanide | 16 | $868 |
| Tramadol Hcl | 56 | $860 |
| Gabapentin | 50 | $804 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $65 | $10,54428 claims |
| Boehringer IngelheimJardiance | $89 | $6,72324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 457 family providers in Rhode Island.
Other family in Warwick
- Carol RobinsonWarwick$82K
- Alicia VatterWarwick$15K
- Talia LeuropaWarwick$7K
- Shelby DefariaWarwick$4K
- Kayla BabcockWarwick$4K
- Ellen HofferWarwick$3K
- Mark ClarkeSmithfield$37K
- Olga FedorenkoCoventry$24K
- Kaleigh RapozaJohnston$14K
- David RamosRiverside$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.